Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Эффективность перевода пациенток в постменопаузе, страдающих гормоночувствительным раком молочной железы ранних стадий, с терапии тамоксифеном на анастрозол (метаанализ)
Эффективность перевода пациенток в постменопаузе, страдающих гормоночувствительным раком молочной железы ранних стадий, с терапии тамоксифеном на анастрозол (метаанализ)
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Полный текст
Список литературы
1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74–108.
2. Current Trials Working Party of the Cancer Research Campaign in Breast Cancer Trials Group. Preliminary results from the cancer research campaign trial evaluating tamoxifen duration in women aged fifty years or older with breast cancer. J Natl Cancer Inst 1996; 88: 1834–9.
3. Swedish Breast Cancer Cooperative Group. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. J Natl Cancer Inst 1996; 88: 1543–9.
4. Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687–717.
5. Fisher B, Costantino JP, Redmond CK, et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994; 86: 527–37.
6. Gradishar W. Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women. Oncology 2005; 69: 1–9.
7. Dorssers LC, Van der Flier S, Brinkman A et al. Tamoxifen resistance in breast cancer: elucidating mechanisms. Drugs 2001; 61: 1721–33.
8. ATAC Trialists’ Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005; 365: 60–2.
9. Boccardo F, Rubagotti A, Puntoni M et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole trial. J Clin Oncol 2005; 23: 5138–47.
10. Boccardo F, Rubagotti A, Puntoni M, and other ITA trialists. Switching to anastrozole (ANA) vs continued tamoxifen (TAM) treatment of early breast cancer (EBC). Updated results of the Italian tamoxifen anastrozole (ITA) trial. Proc Am Soc Clin Oncol 2005; 23: 10s (abstr).
11. Jakesz R, Jonat W, Gnant M, for the ABCSG and the GABG. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005; 366: 455–62.
12. Winer EP, Hudis C, Burstein HJ et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 2005; 23: 619–29.
13. Coombes RC, Hall E, Gibson LJ et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 350: 1081–92.
14. Coombes RC, Paridaens R, Jassem J et al for the Intergroup Exemestane Study (IES). First mature analysis of the Intergroup Exemestane Study. Proc Am Soc Clin Oncol 2006; 24 (abstr).
15. Buzdar A, Robertson JFR, Eiermann W, Nabholtz JM. An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole and exemestane. Cancer 2002; 95: 2006–16.
16. McCloskey E, Eastell R, Lakner G, et al. Initial results from the LEAP study: the first direct comparison of safety parameters between aromatase inhibitors in healthy postmenopausal women. Breast Cancer Res Treat 2005; 94: S101 (abstr).
17. McCloskey E. Effects of third-generation aromatase inhibitors on bone. Eur J Cancer 2006; 42: 1044–51.
18. Nabholtz JM, Gligorov J. Cardiovascular safety profiles of aromatase inhibitors: a comparative review. Drug Safety 2006; 29: 785–801.
19. Punglia RS, Kuntz KM, Winer EP et al. Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis. J Clin Oncol 2005; 23: 5178–87.
20. Cuzick J, Sasieni P, Howell A. Should aromatase inhibitors be used as initial adjuvant treatment or sequenced after tamoxifen? Br J Cancer 2006; 94: 460–4.
21. Goss PE, Ingle JN, Martino S et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005; 97: 1262–71.
22. Fisher B, Dignam J, Bryant J et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 1996; 88: 1529–42.
23. Fisher B, Jeong JH, Dignam J et al. Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer. J Natl Cancer Inst Monogr 2001; 62–6.
24. Buzdar AU. Role of anastrozole in adjuvant therapy for postmenopausal patients. Semin Oncol 2003; 30 (suppl. 16): 21–9.
25. National Comprehensive Cancer Network. NCCN practice guidelines in oncology v.2.2006: breast cancer. http://www.nccn.org (accessed July 24, 2006).
26. Goldhirsch A, Glick JH, Gelber RD et al. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005; 16: 1569–83.
2. Current Trials Working Party of the Cancer Research Campaign in Breast Cancer Trials Group. Preliminary results from the cancer research campaign trial evaluating tamoxifen duration in women aged fifty years or older with breast cancer. J Natl Cancer Inst 1996; 88: 1834–9.
3. Swedish Breast Cancer Cooperative Group. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. J Natl Cancer Inst 1996; 88: 1543–9.
4. Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687–717.
5. Fisher B, Costantino JP, Redmond CK, et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994; 86: 527–37.
6. Gradishar W. Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women. Oncology 2005; 69: 1–9.
7. Dorssers LC, Van der Flier S, Brinkman A et al. Tamoxifen resistance in breast cancer: elucidating mechanisms. Drugs 2001; 61: 1721–33.
8. ATAC Trialists’ Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005; 365: 60–2.
9. Boccardo F, Rubagotti A, Puntoni M et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole trial. J Clin Oncol 2005; 23: 5138–47.
10. Boccardo F, Rubagotti A, Puntoni M, and other ITA trialists. Switching to anastrozole (ANA) vs continued tamoxifen (TAM) treatment of early breast cancer (EBC). Updated results of the Italian tamoxifen anastrozole (ITA) trial. Proc Am Soc Clin Oncol 2005; 23: 10s (abstr).
11. Jakesz R, Jonat W, Gnant M, for the ABCSG and the GABG. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005; 366: 455–62.
12. Winer EP, Hudis C, Burstein HJ et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 2005; 23: 619–29.
13. Coombes RC, Hall E, Gibson LJ et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 350: 1081–92.
14. Coombes RC, Paridaens R, Jassem J et al for the Intergroup Exemestane Study (IES). First mature analysis of the Intergroup Exemestane Study. Proc Am Soc Clin Oncol 2006; 24 (abstr).
15. Buzdar A, Robertson JFR, Eiermann W, Nabholtz JM. An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole and exemestane. Cancer 2002; 95: 2006–16.
16. McCloskey E, Eastell R, Lakner G, et al. Initial results from the LEAP study: the first direct comparison of safety parameters between aromatase inhibitors in healthy postmenopausal women. Breast Cancer Res Treat 2005; 94: S101 (abstr).
17. McCloskey E. Effects of third-generation aromatase inhibitors on bone. Eur J Cancer 2006; 42: 1044–51.
18. Nabholtz JM, Gligorov J. Cardiovascular safety profiles of aromatase inhibitors: a comparative review. Drug Safety 2006; 29: 785–801.
19. Punglia RS, Kuntz KM, Winer EP et al. Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis. J Clin Oncol 2005; 23: 5178–87.
20. Cuzick J, Sasieni P, Howell A. Should aromatase inhibitors be used as initial adjuvant treatment or sequenced after tamoxifen? Br J Cancer 2006; 94: 460–4.
21. Goss PE, Ingle JN, Martino S et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005; 97: 1262–71.
22. Fisher B, Dignam J, Bryant J et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 1996; 88: 1529–42.
23. Fisher B, Jeong JH, Dignam J et al. Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer. J Natl Cancer Inst Monogr 2001; 62–6.
24. Buzdar AU. Role of anastrozole in adjuvant therapy for postmenopausal patients. Semin Oncol 2003; 30 (suppl. 16): 21–9.
25. National Comprehensive Cancer Network. NCCN practice guidelines in oncology v.2.2006: breast cancer. http://www.nccn.org (accessed July 24, 2006).
26. Goldhirsch A, Glick JH, Gelber RD et al. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005; 16: 1569–83.
Авторы
________________________________________________
Источник: Lancet Oncol 2006; 7: 991–96.
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.